Literature DB >> 9797229

Fluconazole versus Candida albicans: a complex relationship.

J R Graybill1, E Montalbo, W R Kirkpatrick, M F Luther, S G Revankar, T F Patterson.   

Abstract

A murine model of systemic candidiasis was used to assess the virulence of serial Candida albicans strains for which fluconazole MICs were increasing. Serial isolates from five patients with 17 episodes of oropharyngeal candidiasis were evaluated. The MICs for these isolates exhibited at least an eightfold progressive increase from susceptible (MIC < 8 microg/ml; range, 0.25 to 4 microg/ml) to resistant (MIC >/= 16 microg/ml; range, 16 to >/=128 microg/ml). Virulence of the serial isolates from three of five patients showed a more than fivefold progressive decrease in the dose accounting for 50% mortality and was associated with development of fluconazole resistance. Low doses of fluconazole prolonged survival of mice infected with susceptible yeasts but failed to prolong survival following challenge with a resistant strain. In addition, a decreased burden of renal infection was noted in mice challenged with two of the three resistant strains. This was consistent with reduced virulence. Fluconazole did not further decrease the level of infection. In the isolates with a decrease in virulence, two exhibited overexpression of CDR, which encodes an ABC drug efflux pump. In contrast, serial isolates from the remaining two patients with the development of resistance did not demonstrate a change in virulence and fluconazole remained effective in prolonging survival, although significantly higher doses of fluconazole were required for efficacy. Resistant isolates from both of these patients exhibited overexpression of MDR. This study demonstrates that decreased virulence of serial C. albicans isolates is associated with increasing fluconazole MICs in some cases but not in others and shows that these low-virulence strains may not consistently cause infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797229      PMCID: PMC105969     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Reduced virulence of Candida albicans mutants affected in multidrug resistance.

Authors:  J M Becker; L K Henry; W Jiang; Y Koltin
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis.

Authors:  F Barchiesi; R J Hollis; M Del Poeta; D A McGough; G Scalise; M G Rinaldi; M A Pfaller
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

4.  Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans.

Authors:  G Arancia; A Molinari; P Crateri; A Stringaro; C Ramoni; M L Dupuis; M J Gomez; A Torosantucci; A Cassone
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS.

Authors:  F Barchiesi; R J Hollis; D A McGough; G Scalise; M G Rinaldi; M A Pfaller
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

6.  Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  J L Lopez-Ribot; R K McAtee; L N Lee; W R Kirkpatrick; T C White; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans.

Authors:  C M Ausiello; F Urbani; S Gessani; G C Spagnoli; M J Gomez; A Cassone
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

8.  Differential susceptibility of yeast and hyphal forms of Candida albicans to proteolytic activity of macrophages.

Authors:  E Blasi; L Pitzurra; A R Chimienti; R Mazzolla; M Puliti; R Barluzzi; F Bistoni
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients.

Authors:  D C Lamb; A Corran; B C Baldwin; J Kwon-Chung; S L Kelly
Journal:  FEBS Lett       Date:  1995-07-17       Impact factor: 4.124

View more
  20 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination.

Authors:  R K Li; C M Elie; G E Clayton; M A Ciblak
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Cell Wall Changes in Amphotericin B-Resistant Strains from Candida tropicalis and Relationship with the Immune Responses Elicited by the Host.

Authors:  Ana C Mesa-Arango; Cristina Rueda; Elvira Román; Jessica Quintin; María C Terrón; Daniel Luque; Mihai G Netea; Jesus Pla; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

4.  Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole.

Authors:  T Wu; K Wright; S F Hurst; C J Morrison
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 5.  Potential role of phospholipases in virulence and fungal pathogenesis.

Authors:  M A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

6.  Functional analysis of CaIPT1, a sphingolipid biosynthetic gene involved in multidrug resistance and morphogenesis of Candida albicans.

Authors:  Tulika Prasad; Preeti Saini; Naseem Akhtar Gaur; Ram A Vishwakarma; Luqman Ahmad Khan; Qazi M Rizwanul Haq; Rajendra Prasad
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Authors:  J L Lopez-Ribot; R K McAtee; S Perea; W R Kirkpatrick; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

9.  Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  J L Lopez-Ribot; R K McAtee; L N Lee; W R Kirkpatrick; T C White; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.

Authors:  Sélène Ferrari; Françoise Ischer; David Calabrese; Brunella Posteraro; Maurizio Sanguinetti; Giovanni Fadda; Bettina Rohde; Christopher Bauser; Oliver Bader; Dominique Sanglard
Journal:  PLoS Pathog       Date:  2009-01-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.